The Medical Takeaways from Remi Bader's GLP-1 Story

The Public Record: What Remi Bader Has Confirmed

Remi Bader, a plus-size model and content creator with millions of followers across TikTok and Instagram, publicly confirmed in 2023 that she had used Ozempic for weight loss. She did not frame the experience as a success story. In interviews and social media posts, Bader described losing weight on the medication, then discontinuing it, and subsequently regaining more weight than she had originally lost.

In a September 2023 appearance on the Not Skinny But Not Fat podcast, Bader stated that she "gained double back" after stopping the drug. She has been direct about the emotional and physical toll of that cycle. By 2024, Bader publicly disclosed that she had undergone bariatric surgery, citing it as a more sustainable path after her GLP-1 experience.

This is not speculation. Bader herself has spoken about these decisions on camera, in print interviews, and on her own social channels.

What the Clinical Data Says About GLP-1 Discontinuation

Bader's experience is not an outlier. The STEP 1 trial extension data, published in Diabetes, Obesity and Metabolism in 2022, tracked participants who had lost an average of 17.3% of body weight on semaglutide 2.4 mg over 68 weeks. One year after discontinuation, participants regained approximately two-thirds of the weight they had lost.

The pattern is consistent across the GLP-1 class. A 2023 analysis in JAMA examining tirzepatide (Mounjaro/Zepbound) discontinuation found similar rebound trajectories. Patients who stopped tirzepatide after 36 weeks of treatment regained roughly half their lost weight over the following year.

The mechanism is not complicated. GLP-1 receptor agonists like semaglutide reduce appetite by acting on hypothalamic circuits that regulate hunger and satiety. They slow gastric emptying. They appear to reduce food reward signaling. When the drug leaves the system, those effects reverse. Appetite returns to baseline, and the body's weight-regulation set point reasserts itself through compensatory hormonal shifts, including increases in ghrelin and decreases in leptin sensitivity.

This is not a failure of willpower. It is predictable endocrinology.

The "Double Rebound" Question

Bader's claim that she gained back more than she lost raises a question patients frequently ask: can you end up heavier than where you started?

The STEP 1 extension data did not show overshoot beyond baseline as a group-level finding. On average, patients returned toward (but not past) their starting weight. However, individual variation was substantial. Some participants did cross their original baseline.

A 2024 retrospective study published in Obesity found that a subset of patients who discontinued semaglutide experienced weight gain beyond pre-treatment levels, particularly those with higher baseline BMI and shorter treatment durations. The researchers hypothesized that rapid weight loss followed by abrupt cessation may create metabolic conditions, including adaptive thermogenesis and altered gut hormone profiles, that favor overshooting the original set point.

The HealthRX.com Medical Team's reading of this evidence: overshoot beyond baseline is not guaranteed, but it is a documented possibility. Patients who stop GLP-1 therapy abruptly after significant weight loss should understand this risk before discontinuing.

What Bader's Timeline Reveals About Dose-Response and Duration

One detail Bader has not publicly specified is her dose or treatment duration. This matters clinically.

Semaglutide for weight management (Wegovy) follows a five-step dose escalation over 16 weeks, starting at 0.25 mg weekly and climbing to the maintenance dose of 2.4 mg. Many patients who use the diabetes formulation (Ozempic, which Bader identified by name) may not reach the higher doses studied in the STEP trials, as Ozempic's maximum labeled dose is 2 mg and it is not FDA-approved for weight management.

This distinction matters. The STEP 1 trial used 2.4 mg semaglutide. The weight-loss magnitude and the subsequent rebound data are anchored to that dose. Patients taking lower doses for shorter periods may experience different trajectories, and the limited data available suggests that shorter treatment duration correlates with faster and more complete regain.

The HealthRX.com Medical Team notes: when a patient reports that a GLP-1 "didn't work" or produced a severe rebound, the clinical question is always what dose they reached, how long they were on it, and whether the discontinuation was gradual or abrupt. These details shape outcomes dramatically.

Side Effects That Drive Discontinuation

Bader has spoken publicly about experiencing side effects on Ozempic, though she has not catalogued them in clinical detail. The most commonly reported adverse effects of semaglutide at the 2.4 mg dose, per the STEP 1 trial data, include:

• Nausea: reported by 44% of participants (vs. 17% placebo)
• Diarrhea: 30% (vs. 16% placebo)
• Vomiting: 24% (vs. 6% placebo)
• Constipation: 24% (vs. 11% placebo)

These GI side effects are the primary reason patients discontinue therapy. In the STEP trials, approximately 7% of semaglutide-treated patients withdrew due to adverse events. Real-world discontinuation rates are higher. A 2023 analysis of pharmacy claims data found that roughly 50% of patients prescribed semaglutide for weight loss had discontinued within the first year, with GI intolerance and cost cited as the leading reasons.

For patients who tolerate GLP-1 therapy well, the clinical evidence favors long-term continuation. The drugs were studied and approved with the understanding that obesity is a chronic condition requiring chronic treatment, not a short course that produces permanent results.

The Bariatric Surgery Decision

Bader's subsequent choice to pursue bariatric surgery is worth examining in clinical context. Bariatric procedures (sleeve gastrectomy, gastric bypass) remain the most durable intervention for severe obesity, with 10-year data showing sustained weight loss of 20 to 30% depending on the procedure.

Some patients arrive at bariatric surgery after GLP-1 therapy fails to produce adequate results or proves intolerable. Others, like Bader, arrive after discontinuation-related regain. A growing body of clinical opinion, reflected in 2023 ASMBS/IFSO guidelines, positions pharmacotherapy and surgery as complementary rather than competing tools. Some centers now use GLP-1 agonists as a bridge to surgery or as a post-surgical adjunct to prevent regain.

The HealthRX.com Medical Team emphasizes: bariatric surgery after GLP-1 discontinuation is not a "failure." It represents a rational escalation within a treatment algorithm for a chronic disease with multiple evidence-based interventions.

What Non-Celebrity Patients Should Take from This

Bader's story is valuable precisely because it is public, confirmed, and representative of a common clinical pattern. The HealthRX.com Medical Team identifies five concrete takeaways:

At a glance

• GLP-1 therapy is not a short course. The evidence supports indefinite use for weight maintenance. Patients should enter treatment with that expectation.
• Discontinuation rebound is the rule, not the exception. STEP 1 extension data shows two-thirds of lost weight returns within a year of stopping.
• Dose and duration matter. Subtherapeutic doses and abbreviated treatment courses are associated with worse outcomes.
• Side effects are common but often manageable. Slow dose titration and dietary modification reduce GI symptoms for most patients.
• Bariatric surgery remains an option. Prior GLP-1 use does not preclude surgical candidacy. The two approaches can be complementary.

Frequently asked questions

›

›

›

›

›

References

• Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." NEJM. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
• Wilding JPH et al. "Weight regain and cardiometabolic effects after withdrawal of semaglutide." Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/
• Jastreboff AM et al. "Tirzepatide for Obesity, Withdrawing Treatment and Weight Regain." JAMA. 2023. https://jamanetwork.com/journals/jama/fullarticle/2801271
• Wegovy prescribing information. FDA. https://www.accessdata.fda.gov/drugsatfda_cen/label.do?id=215256
• Arterburn DE et al. "Long-term outcomes of bariatric surgery." JAMA. 2020. https://pubmed.ncbi.nlm.nih.gov/36068963/
• ASMBS/IFSO 2023 guidelines on metabolic and bariatric surgery. https://pubmed.ncbi.nlm.nih.gov/37982557/
• People. "Remi Bader Tried Ozempic, Lost Weight, Then Gained It All Back, and More." 2023. https://people.com/remi-bader-tried-ozempic-lost-weight-gained-back-more-7568061/
• People. "Remi Bader Reveals She Had Weight-Loss Surgery." 2024. https://people.com/remi-bader-reveals-she-had-weight-loss-surgery-8729498/